Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 29, Issue 9, 2002, Pages 777-782

  Mori, T ^a   Okamoto, S ^a   Watanabe, R ^a   Yajima, T ^a   Iwao, Y ^a   Yamazaki, R ^a   Nakazato, T ^a   Sato, N ^a   Iguchi, T ^a   Nagayama, H ^a   Takayama, N ^a   Hibi, T ^a   Ikeda, Y ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus; Ganciclovir; Hematopoietic stem cell transplantation; Preemptive therapy; Real time PCR

Indexed keywords

CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; GLUCOCORTICOID; HYPERIMMUNE GLOBULIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GASTROENTERITIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RETINITIS; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 0036272556     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703542     Document Type: Article

References (36)

1. Risk factors for cytomegalovirus infection after human marrow transplantation
2. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
3. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplantation
4. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
5. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients
6. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
7. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplantation: Correlation with CMV disease and effect of ganciclovir prophylaxis
8. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
9. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
10. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy
11. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
12. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: A single-center experience
13. Risk-adapted preemptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
14. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hamatopoietic stem cell transplantation: A single-center experience in Japan
15. Consensus conference on acute GvHD grading
16. Real time quantitative PCR
17. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method
18. Successful monitoring of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipient
19. Cytomegalovirus antigen detection in peripheral leukocytes after allogeneic marrow transplantation
20. Development of a method for direct quantification of cytomegalovirus antigenemia by flow cytometry
21. Detection of cytomegalovirus proteins by flowcytometry in the blood of patients undergoing hematopoietic stem cell transplantation
22. Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients
23. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
24. Use of a semiquantitative PCR for cytomegalovirus DNA as a basis for preemptive antiviral therapy in allogeneic bone marrow transplant patients
25. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: Comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
26. Evaluation of the Amplicor CMV test for direct detection of cytomegalovirus in plasma specimens
27. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation
28. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease
29. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients
30. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants
31. Comparative evaluation of the cytomegalovirus DNA load in polymorphonuclear leukocytes and plasma of human immunodeficiency virus-infected subjects
32. Rising level of human cyomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection
33. Comparison of the Murex Hybrid Capture CMV DNA (v2.0) assay and the pp65 CMV antigenemia test for the detection and quantification of CMV in blood samples from immunocompromised patients
34. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes
35. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin
36. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation